Extract
Allergen inhalation challenge triggers well-defined airway responses in mild, allergic asthmatics. Some individuals develop only an isolated early response (early responders (ERs)) characterised by acute airway smooth muscle constriction immediately following allergen inhalation. Others develop a late response (dual responders (DRs)) that begins 3–4 h later, resulting in prolonged reduction of airway function, associated with cellular infiltration, inflammation and hyperresponsiveness of the airways [1]. It is not well understood how certain individuals are protected from developing a late response. Our previous research identified novel RNA transcripts in peripheral blood that are predictive of asthmatics who could develop a late response. Our findings pointed towards the presence of inherent differences underlying molecular mechanisms that predispose asthmatic individuals to the late response [2].
Abstract
Cholinergic synapse pathway gene polymorphisms may play a role in regulating a type of asthmatic airway response triggered upon allergen challenge http://bit.ly/2lJx1VG
Footnotes
This study is registered at www.clinicaltrials.gov with identifier number NCT01113697.
Author contributions: A. Rajasekaran, G.M. Gauvreau and S.J. Tebbutt conceived and designed the study. D. He, A. Yue, G.M. Gauvreau, J.M. FitzGerald, L-P. Boulet and P.M. O'Byrne performed the experimental procedures. A. Rajasekaran, A. Yue, A. Singh, C.P. Shannon and S.J. Tebbutt analysed and interpreted the data. A. Rajasekaran and S.J. Tebbutt prepared the manuscript.
Conflict of interest: A. Rajasekaran has nothing to disclose.
Conflict of interest: D. He has nothing to disclose.
Conflict of interest: A. Yue has nothing to disclose.
Conflict of interest: A. Singh has nothing to disclose.
Conflict of interest: C.P. Shannon has nothing to disclose.
Conflict of interest J.M. FitzGerald has nothing to disclose.
Conflict of interest: L-P. Boulet reports research grants for participation in multicentre studies from AstraZeneca, Boston Scientific, GlaxoSmithKline, Hoffman La Roche, Novartis, Ono Pharma, Sanofi and Takeda; support for investigator-initiated research projects from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck and Takeda; consulting and advisory boards for AstraZeneca, Novartis and Methapharm; author royalties from Up To Date (occupational asthma); nonprofit grants for production of educational materials from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Frosst and Novartis; renumeration of conference fees from AstraZeneca, GlaxoSmithKline, Merck and Novartis; support for participation in conferences and meetings from Novartis and Takeda; he is a past president of the Canadian Thoracic Society and a member of its Respiratory Guidelines Committee; he is Chair of the Board of Directors of the Global Initiative for Asthma (GINA); he is Chair of the GINA Dissemination and Implementation Committee; he holds the Laval University Chair on Knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health; he is a member of scientific committees for the American College of Chest Physicians, the American Thoracic Society, the European Respiratory Society and the World Allergy Organization; and he is the first Vice-President of the global asthma organisation InterAsma.
Conflict of interest: P.M. O'Byrne reports membership of a joint oversight board for a LABA safety study; consultancy for AstraZeneca, GSK and Chiesi; and grants or grants pending from AstraZeneca, Genentech and Novartis.
Conflict of interest: G.M. Gauvreau has nothing to disclose.
Conflict of interest: S.J. Tebbutt has nothing to disclose.
Support statement: This research was supported by funding from AllerGen NCE Inc. (Allergy, Genes and Environment Network), PROOF Centre of Excellence, British Columbia Lung Association and BioTalent Canada.
- Received April 29, 2019.
- Accepted August 25, 2019.
- Copyright ©ERS 2019
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.